Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Rexahn Pharmaceuticals (RNN)

Rexahn Pharmaceuticals (RNN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,060
  • Shares Outstanding, K 4,019
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,370 K
  • 60-Month Beta 0.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.32
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.18
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/13/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.85
  • Number of Estimates 3
  • High Estimate -0.70
  • Low Estimate -0.95
  • Prior Year -1.80
  • Growth Rate Est. (year over year) +52.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.71 +11.25%
on 05/20/19
6.10 -14.10%
on 05/08/19
-0.65 (-11.04%)
since 05/07/19
3-Month
4.71 +11.25%
on 05/20/19
9.18 -42.92%
on 04/16/19
-1.45 (-21.66%)
since 03/07/19
52-Week
4.71 +11.25%
on 05/20/19
23.64 -77.83%
on 06/11/18
-16.96 (-76.40%)
since 06/07/18

Most Recent Stories

More News
Ocuphire to Participate in Upcoming Virtual Healthcare Investor Conferences in September

Ocuphire Pharma, Inc., a privately-held clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced...

RNN : 5.24 (+0.19%)
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors

, /PRNewswire/ -- (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases,...

RNN : 5.24 (+0.19%)
NRBO : 5.62 (-3.60%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Rexahn Pharmaceuticals, Inc.

, /PRNewswire/ --  is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Rexahn Pharmaceuticals, Inc. ("REXN" or the "Company") (NASDAQ: REXN)...

RNN : 5.24 (+0.19%)
REXN : 2.05 (-1.91%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Rexahn Pharmaceuticals, Inc. with Ocuphire Pharma, Inc. is Fair to REXN Shareholders

New York, New York--(Newsfile Corp. - June 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

RNN : 5.24 (+0.19%)
REXN : 2.05 (-1.91%)
Rexahn to Explore Strategic Alternatives

Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Rexahn has engaged Oppenheimer...

RNN : 5.24 (+0.19%)
REXN : 2.05 (-1.91%)
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development

Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced...

RNN : 5.24 (+0.19%)
REXN : 2.05 (-1.91%)
Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. as VP, Clinical Development

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as VP, Clinical Development. Dr. Eisen is a translational...

ACOR : 0.5114 (-3.51%)
RNN : 5.24 (+0.19%)
Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced...

RNN : 5.24 (+0.19%)
Analysis: Positioning to Benefit within Nordic American Tankers, Safeguard Scientifics, Permian Basin Royalty Trust, Coda Octopus Group, Rexahn Pharmaceuticals, and Diversified Restaurant -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nordic American Tankers Limited...

NAT : 3.53 (-4.08%)
SFE : 5.28 (-1.68%)
PBT : 2.73 (-0.73%)
CODA : 5.57 (-0.36%)
RNN : 5.24 (+0.19%)
SAUC : 1.04 (unch)
Biotech Brief: Optimism Rising for Cancer Treatment Advancements in 2019

Financialnewsmedia.com News Commentary

AXSM : 79.64 (-2.01%)
RNN : 5.24 (+0.19%)
TEVA : 8.78 (-0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RNN with:

Business Summary

REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat...

See More

Key Turning Points

2nd Resistance Point 5.69
1st Resistance Point 5.46
Last Price 5.24
1st Support Level 4.99
2nd Support Level 4.75

See More

52-Week High 23.64
Fibonacci 61.8% 16.41
Fibonacci 50% 14.17
Fibonacci 38.2% 11.94
Last Price 5.24
52-Week Low 4.71

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar